Search Results - "SIDOR, Carolyn"

Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial by Matei, Daniela, Schilder, Jeanne, Sutton, Gregory, Perkins, Susan, Breen, Tim, Quon, Check, Sidor, Carolyn

“…Abstract Background 2-Methoxyestradiol (Panzem®, 2ME2) is an endogenous metabolite of estradiol that destabilizes microtubules and exerts anti-angiogenic…”
Get full text

ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action by Fletcher, Graham C, Brokx, Richard D, Denny, Trisha A, Hembrough, Todd A, Plum, Stacy M, Fogler, William E, Sidor, Carolyn F, Bray, Mark R

“…ENMD-2076 is a novel orally active, small molecule kinase inhibitor with a mechanism of action involving several pathways key to tumor growth and survival:…”
Get full text

Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies by TEVAARWERK, Amyej, HOLEN, Kyle D, ALBERTI, Dona B, SIDOR, Carolyn, ARNOTT, Jamie, QUON, Check, WILDING, George, LIU, Glenn

“…Purpose: 2-Methoxyestradiol (2ME2; Panzem) is an endogenous, estradiol-17β metabolite that at pharmacologic doses exerts antimitotic and antiangiogenic…”
Get full text

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer by Matulonis, Ursula A, Lee, Julie, Lasonde, Brian, Tew, William P, Yehwalashet, Afra, Matei, Daniela, Behbakht, Kian, Grothusen, Jill, Fleming, Gini, Lee, Nita K, Arnott, Jamie, Bray, Mark R, Fletcher, Graham, Brokx, Richard D, Castonguay, Vincent, Mackay, Helen, Sidor, Carolyn F, Oza, Amit M

“…Abstract Purpose The purpose was to assess the activity and side effect profile of ENMD-2076, an oral anti-angiogenic and anti-proliferative kinase inhibitor,…”
Get full text

Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors by KULKE, Matthew H, BERGSLAND, Emily K, MICHELINI, Ann, KINSELLA, Kate, VENOOK, Alan P, FUCHS, Charles S, RYAN, David P, ENZINGER, Peter C, LYNCH, Thomas J, ZHU, Andrew X, MEYERHARDT, Jeffrey A, HEYMACH, John V, FOGLER, William E, SIDOR, Carolyn

“…Endostatin is a 20-kd proteolytic fragment of collagen XVIII that, in preclinical studies, has been shown to have antiangiogenic and antitumor activity. Both…”
Get full text

A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer by SWEENEY, Christopher, LIU, Glenn, WILDING, George, YIANNOUTSOS, Constantin, KOLESAR, Jill, HORVATH, Dorothea, STAAB, Mary Jane, FIFE, Karen, ARMSTRONG, Victoria, TRESTON, Antliofiy, SIDOR, Carolyn

“…Purpose: To determine whether the preclinical antitumor and antiangiogenic activity of 2-methoxyestradiol can be translated to the clinic. Experimental Design:…”
Get full text

Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis by Plum, Stacy M, Park, Eun J, Strawn, Steve J, Moore, Elizabeth G, Sidor, Carolyn F, Fogler, William E

“…A critical component of disease progression in rheumatoid arthritis (RA) involves neovascularization associated with pannus formation. 2-methoxyestradiol…”
Get full text

Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma by RAJKUMAR, S. Vincent, RICHARDSON, Paul G, LACY, Martha Q, DISPENZIERI, Angela, GREIPP, Philip R, WITZIG, Thomas E, SCHLOSSMAN, Robert, SIDOR, Carolyn F, ANDERSON, Kenneth C, GERTZ, Morie A

“…Purpose: 2-Methoxyestradiol (2ME2) is an endogenous product of estradiol metabolism with antiangiogenic and antineoplastic properties. We report on the first…”
Get full text

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198 by LaVallee, Theresa M, Burke, Patricia A, Swartz, Glenn M, Hamel, Ernest, Agoston, Gregory E, Shah, Jamshed, Suwandi, Lita, Hanson, Art D, Fogler, William E, Sidor, Carolyn F, Treston, Anthony M

“…Clinical studies using the microtubule-targeting agent 2-methoxyestradiol (2ME2; Panzem) in cancer patients show that treatment is associated with clinical…”
Get full text

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD‐2076, against multiple myeloma by Wang, Xiaojing, Sinn, Anthony L., Pollok, Karen, Sandusky, George, Zhang, Shuhong, Chen, Li, Liang, Jing, Crean, Colin D., Suvannasankha, Attaya, Abonour, Rafat, Sidor, Carolyn, Bray, Mark R., Farag, Sherif S.

“…Summary ENMD‐2076 is a novel, orally‐active molecule that has been shown to have significant activity against aurora and multiple receptor tyrosine kinases. We…”
Get full text

Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily by EDER, Joseph P, SUPKO, Jeffrey G, CONNORS, Susan, KEOGAN, Mary T, JANICEK, Milos J, FOGLER, William E, SCHNIPPER, Lowell, KINCHLA, Nancy, SIDOR, Carolyn, PHILLIPS, Eric, FOLKMAN, Judah, KUFE, Donald W, CLARK, Jeffrey W, PUCHALSKI, Thomas A, GARCIA-CARBONERO, Rocio, RYAN, David P, SHULMAN, Lawrence N, PROPER, Joann, KIRVAN, Moira, RATTNER, Barbara

“…To perform a phase I trial of recombinant human endostatin (rhEndostatin; EntreMed, Rockville, MD) given as a daily 20-minute intravenous (IV) injection in…”
Get full text

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC) by Harrison, Michael R., Hahn, Noah M., Pili, Roberto, Oh, William K., Hammers, Hans, Sweeney, Christopher, Kim, KyungMann, Perlman, Scott, Arnott, Jamie, Sidor, Carolyn, Wilding, George, Liu, Glenn

“…Summary Purpose : 2ME2 (Panzem®) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic activity. Preclinical data support…”
Get full text

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors by Kulke, Matthew H., Chan, Jennifer A., Meyerhardt, Jeffrey A., Zhu, Andrew X., Abrams, Thomas A., Blaszkowsky, Lawrence S., Regan, Eileen, Sidor, Carolyn, Fuchs, Charles S.

“…Purpose Angiogenesis inhibition has emerged as a potentially promising treatment strategy for neuroendocrine tumors. 2-Methoxyestradiol (2ME2; Panzem ® ) is a…”
Get full text

A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors by Bauer, Todd Michael, Infante, Jeffrey R., Eder, Joseph Paul, LoRusso, Patricia, LaVallee, Theresa, Gedrich, Rich, Sidor, Carolyn, Falchook, Gerald Steven

“…Abstract only…”
Get full text

A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia by Yee, Karen W. L., Chen, Hsiao-Wei T., Hedley, David W., Chow, Sue, Brandwein, Joseph, Schuh, Andre C., Schimmer, Aaron D., Gupta, Vikas, Sanfelice, Deborah, Johnson, Tara, Le, Lisa W., Arnott, Jamie, Bray, Mark R., Sidor, Carolyn, Minden, Mark D.

“…Summary ENMD-2076 is a novel, orally-active molecule that inhibits Aurora A kinase, as well as c-Kit, FLT3 and VEGFR2. A phase I study was conducted to…”
Get full text

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors by DIAMOND, Jennifer R, BASTOS, Bruno R, MORROW, Mark, ARNOTT, Jamie, BRAY, Mark R, SIDOR, Carolyn, MESSERSMITH, Wells, SHAPIRO, Geoffrey I, HANSEN, Ryan J, GUSTAFSON, Daniel L, GAIL ECKHARDT, S, KWAK, Eunice L, PANDYA, Shuchi S, FLETCHER, Graham C, PITTS, Todd M, KULIKOWSKI, Gillian N

“…ENMD-2076 is a unique orally bioavailable Aurora kinase and VEGFR inhibitor. The purpose of this phase 1 study of ENMD-2076 was to determine the MTD,…”
Get full text

Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer by James, Jehana, Murry, Daryl J, Treston, Anthony M, Storniolo, Anna Maria, Sledge, George W, Sidor, Carolyn, Miller, Kathy D

“…We report the first phase I trials of 2-methoxyestradiol (2ME2, Panzem Capsules, EntreMed, Rockville, MD), alone and in combination with docetaxel, in patients…”
Get full text

Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design by Tevaarwerk, Amye, Wilding, George, Eickhoff, Jens, Chappell, Rick, Sidor, Carolyn, Arnott, Jamie, Bailey, Howard, Schelman, William, Liu, Glenn

“…Summary Background MKC-1 is an oral cell-cycle inhibitor with broad antitumor activity in preclinical models. Clinical studies demonstrated modest antitumor…”
Get full text

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer by Zhou, Qing, Gustafson, Daniel, Nallapareddy, Sujatha, Diab, Sami, Leong, Stephen, Lewis, Karl, Gore, Lia, Messersmith, Wells A., Treston, Anthony M., Eckhardt, S. Gail, Sidor, Carolyn, Camidge, D. Ross

“…Summary Background 2-methoxyestradiol (2ME2) is an estradiol-17β metabolite with antiproliferative and antiangiogenic activities. ENMD-1198 is an analog of…”
Get full text

Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results by Farag, Sherif, Zhang, Shuhong, Suvannasankha, Attaya, Liang, Jing, O'Bryant, Robyn, Lisa, Wood, Gupta, Sushil, Bray, Mark, Sidor, Carolyn Fowler, Abonour, Rafat

“…Abstract 1957 Despite recent improvements, MM remains incurable, indicating the need for continued investigation of novel agents. ENMD-2076 is a novel, orally…”
Get full text